透過您的圖書館登入
IP:13.59.243.194
  • 期刊

以人類基因重組副甲狀腺素治療服用雙磷酸類藥物引發顎骨壞死-病例報告

Treatment of Bisphosphonate-related Osteonecrosis of Jaw with Recombinant Human Parathyroid Hormone (1-34)-Case Report

摘要


服用雙磷酸類藥物引發顎骨壞死的病例自從2003年開始陸續在美國被提出,主要是因爲此類藥物可抑制噬骨細胞形成,降低正常骨頭的重塑作用,造成口腔黏膜無法癒合,產生顎骨壞死的現象。國內因此類藥物引發顎骨壞死的病例也日益增多,且對於手術治療效果不盡理想。除了手術治療外,使用人類基因重組副甲狀腺素(FORTEO(上標 TM)),可直接刺激骨母細胞活性,促進骨質生成,治療顎骨壞死。本院利用此藥物配合手術,成功治癒服用雙磷酸類藥物引發顎骨壞死病患,提供針對服用雙磷酸類藥物引發顎骨壞死病例的治療參考。

並列摘要


More and more cases of bisphosphonate-related osteonecrosis were presented in America since 2003, due to the drugs of bisphosphonte can inhibit the formation of osteoclasts and subsequently retard the process of normal bone remodeling. If the bone is traumatized or infected, the overlying mucosa will not heal and the bone exposure appears with the progression of osteonecrosis. The problems of bisphosphonste-related osteonecrosis of jaws also increase in Taiwan and the response to conservative surgical treatment is not well. Besides the surgical intervention, the use of human recombinant parathyroid hormones (FORTEOTM) enhances osteoblast activities and normal bone formation for the treatment of osteonecrosis. The case we presented was conservatively treated with combination of debridement and parathyroid hormone. The successful treatment outcome implies consideration of parathyroid hormone use for the treatment of bisphosphonate-related osteonecrosis of jaws.

並列關鍵字

bisphosphonate osteonecrosis jaw bone rhPTH

延伸閱讀